4.5 Article

Assessment of rationality of available fixed dose combinations of antibiotics in India

期刊

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 20, 期 5, 页码 797-808

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/14787210.2022.2015324

关键词

Antimicrobials; Fixed Dose Combinations; irrational; probiotics; topical antibiotics

向作者/读者索取更多资源

India is one of the largest consumers of antibiotics and the easy availability and growing sales of Fixed Dose Combinations (FDCs) of antibiotics can worsen Antimicrobial Resistance (AMR). A study found that over 90% of existing FDCs were irrational, with two thirds of them being unapproved or banned from use in the country. Despite regulatory awareness, there is an urgent need to reassess these FDCs in order to promote prudent antibiotic use.
Objective India is among the largest consumers of antibiotics. Easy availability and growing sales of Fixed Dose Combinations (FDCs) of antibiotics can worsen Antimicrobial Resistance (AMR). There is lack of comprehensive data on available antibiotic FDC formulations, their dose strengths and adequacy of scientific evidence regarding their efficacy, safety and suitability for human use. In the present work, we aimed at addressing this knowledge gap. Methods Availability of FDCs was ascertained from the Current Index of Medical Specialties (CIMS) [Issue Jan-April 2020]. Customized data abstraction form was used to capture pertinent information for these FDCs. Assessment of rationality was done based on standard parameters. Results More than 90% of the existing FDCs were found to be irrational; with two third of them being unapproved and or banned from use in the country. Conclusions Although the regulatory agency has already taken cognizance of the seriousness of the matter; there is an urgent need to revisit these FDCs to promote prudent antibiotic use. Expert opinion High antibiotic use is associated with antimicrobial resistance; it is imperative that all factors which lead to high antibiotic use are adequately addressed. Easy availability of fixed dose combinations (FDCs) has begun to catch the attention of regulators in developing economies like India leading to a ban of 330 FDCs of which 19% were antibiotic combinations. The continuing presence and increasing sales of these irrational FDCs is a concern for effective antimicrobial stewardship.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据